Valuation : PYC Therapeutics Limited

Market Cap 2.21B 1.59B 1.37B 1.28B 1.17B 2.21B 152B 15.22B 5.94B 76.6B 5.96B 5.83B 254B P/E 2027 *
-24.4x
P/E 2028 * -26.7x
Enterprise Value 1.63B 1.17B 1.01B 947M 865M 1.63B 112B 11.24B 4.38B 56.56B 4.4B 4.31B 188B EV / Sales 2027 *
-
EV / Sales 2028 * 11.1x
Free-Float
70.64%
Yield 2027 *
-
Yield 2028 * -
1 day-0.44%
1 week+8.70%
Current month+32.35%
1 month+38.46%
3 months+61.87%
6 months+49.50%
Current year+35.95%
1 week 2.04
Extreme 2.04
2.31
1 month 1.62
Extreme 1.625
2.31
Current year 1.04
Extreme 1.045
2.31
1 year 0.85
Extreme 0.847
2.31
3 years 0.52
Extreme 0.52
2.31
5 years 0.5
Extreme 0.5
2.31
10 years 0.15
Extreme 0.15
2.31
Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
General Counsel - 15/06/2026
Director TitleAgeSince
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Chairman 66 18/11/2025
Date Insider Type Main position Quantity % Market Cap.
13/8/26 Free

Chief Executive Officer

4,598,662 0.4676%
13/8/26 Free

Chief Executive Officer

10,477,965 1.0654%
13/8/26 Free

Chief Executive Officer

7,706,503 0.7836%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+8.70%+74.42%+287.93% 1.59B
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.42%-0.08%+79.38%+134.44% 27.61B
Weighted average by Cap. -1.69%-1.00%+95.58%+134.57%

Financials

2027 *2028 *
Net sales - 154M 110M 95.21M 89.27M 81.49M 154M 10.56B 1.06B 413M 5.33B 415M 406M 17.68B
Net income -85.75M -61.52M -53.01M -49.71M -45.37M -85.48M -5.88B -590M -230M -2.97B -231M -226M -9.84B -87.28M -62.62M -53.96M -50.59M -46.18M -87M -5.98B -600M -234M -3.02B -235M -230M -10.02B
Net Debt -579M -415M -358M -335M -306M -577M -39.69B -3.98B -1.55B -20.03B -1.56B -1.53B -66.43B -505M -362M -312M -293M -267M -503M -34.62B -3.47B -1.35B -17.47B -1.36B -1.33B -57.94B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
28/08/26 $2.250 -0.44% 1,548,143
27/08/26 $2.260 +4.15% 2,391,608
26/08/26 $2.170 +4.33% 1,360,907
25/08/26 $2.080 -0.95% 1,361,994
24/08/26 $2.100 +1.45% 2,019,395
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.250AUD
Average target price
3.752AUD
Spread / Average Target
+66.76%

Quarterly revenue - Rate of surprise